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Abstract
Background: The optimization of preventive strategies in patients at high risk of cardiovascular events and the 
evaluation of bottlenecks and limitations of transferring current guidelines to the real world of clinical practice are 
important limiting steps to cardiovascular prevention. Treatment with n-3 polyunsaturated fatty acids improves 
prognosis after myocardial infarction, but evidence of this benefit is lacking in patients at high cardiovascular risk, but 
without a history of myocardial infarction.
Methods/design: Patients were eligible if their general practitioner (GP) considered them at high cardiovascular risk 
because of a cardiovascular disease other than myocardial infarction, or multiple risk factors (at least four major risk 
factors in non-diabetic patients and one in diabetics).
Patients were randomly allocated to treatment with n-3 polyunsaturated fatty acids (1 g daily) or placebo in a double-
blind study and followed up for five years by their GPs to assess the efficacy of the treatment in preventing
cardiovascular mortality (including sudden death) and hospitalization for cardiovascular reasons. The secondary,
epidemiological, aim of the study is to assess whether it is feasible to adopt current guidelines in everyday clinical
practice, with a view to optimizing all the available preventive strategies in people at high cardiovascular risk.
A nation-wide network of 860 GPs admitted 12,513 patients to the study between February 2004 and March 2007. The
mean age was 64 years and 62% were males. Diabetes mellitus plus one or more cardiovascular risk factors was the
main inclusion criterion (47%). About 30% of patients were included because of a history of atherosclerotic
cardiovascular disease, 21% for four or more risk factors, and less than 1% for other reasons.
Discussion: The Rischio and Prevenzione (R&P) project provides a feasible model to test the efficacy of n-3 
polyunsaturated fatty acid therapy in patients at high cardiovascular risk with no history of myocardial infarction, and 
to assess how to implement recommended preventive strategies in general practice.
Trial registration: ClinicalTrials.gov NCT00317707
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Background
Cardiovascular diseases (CVD) are the leading cause of
death in middle-aged and older adults in most European
countries. CVD are also an important cause of disability
and morbidity and the main economic burden for health
care services [1-4].
According to guidelines, patients with established CVD
and those with multiple risk factors are at high cardiovas-
cular (CV) risk and are therefore the main target for pre-
ventive strategies. These have to be tailored to the level of
CV risk rather than aimed "only" at the treatment of indi-
vidual cardiovascular risk factors [5]. Inadequate control
of modifiable risk factors has been documented in vari-
ous surveys [6-12] so there is considerable potential for
improving cardiovascular prevention, especially in every-
day clinical practice
While it is easy to see that general practice is a suitable
setting for large-scale randomized controlled trials
(RCTs) and prospective outcome-oriented studies [13-
15], it is still rare to find general practice-based reports in
the formulation and enforcement of guidelines for pri-
mary care physicians [16]. It is clear that until general
practice itself is directly involved in research programs no
significant or pertinent changes will ever be proposed
and adopted.
Among possible preventive strategies, n-3 polyunsatu-
rated fatty acids of marine origin (n-3 PUFA) are the new-
est and most promising. N-3 PUFA have been evaluated
in pharmacological studies for their antithrombotic and
anti-atherosclerotic effects, and their positive action on
arrhythmias [17,18] has attracted a lot of attention.
After a pilot study to assess the feasibility of a large
intervention study in the setting of general practice
[10,19], the Rischio&Prevenzione (R&P) Study was
launched in 2004. The project was designed to follow a
cohort of patients at high CVD risk but with no history of
myocardial infarction to test the efficacy of n-3 PUFA
therapy, on the top of the other recommended preventive
strategies (including lifestyle intervention and pharmaco-
logical treatments) aimed at optimizing the cardiovascu-
lar risk profile.
Rationale of the n-3 PUFA hypothesis
The cardioprotective role of n-3 PUFAs, notably eicosap-
entaenoic acid (EPA) and docosahexanoic acid (DHA),
referred to as omega-3 fatty acids or fish oil, is supported
by substantial evidence. Most observational studies
report an inverse relation between fish intake and coro-
nary heart disease (CHD) mortality [20-24], especially
sudden cardiac death [25-27]. This protective effect has
been attributed to high EPA and DHA blood concentra-
tions [25,28].
More direct evidence of the cardioprotective effect of
omega-3 fatty acids comes from RCTs in patients with a
history of myocardial infarction (MI). In 2033 post-MI
men, a modest intake of fatty fish (200-400 g/week) or of
n-3 PUFAs (0.5 g/day) reduced total mortality (primarily
CHD deaths) by 29% during the two years of follow-up
[29]. By far the largest trial was the GISSI Prevenzione
study which tested the efficacy of 1 g/day of omega 3 fatty
acids (as EPA and DHA) in 11323 patients with a recent
MI (≤3 months) [17]. After 3.5 years, those receiving
omega-3 fatty acids had a 20% lower relative risk of total
mortality. Sudden death was the most affected cause,
with 45% reduction, and the benefit appeared after only
four months of therapy [18].
These results might be due to an antiharrythmic action
of n-3 PUFAs and are in agreement with evidence from in
vitro studies [30], animal models [31] and human studies
[32].
The antiarrhythmic effect of n-3 PUFAs seems mainly
to be due to electrical stabilization of cardiomyocytes, by
increasing the electrical stimulus required to elicit an
action potential and prolonging the relative refractory
time. This might be through an action on sarcolemmal
ionic channels: n-3 PUFAs inhibit fast voltage-dependent
Na+ currents, L-type calcium currents, and some potas-
sium current components [33].
n-3 PUFAs may also exert beneficial effects through
mechanisms such as antithrombotic, antiinflammatory,
anti-atherogenic and triglyceride lowering actions,
although these have been reported with higher doses
than those needed to prevent arrhythmias in clinical set-
tings (1 g/day n-3 PUFAs). These data underlie the Amer-
ican Heart Association recommendations that patients
with CHD should consume 1 g/day of EPA+ DHA [34].
Methods
Study design and population
The R&P study is an ongoing large-scale, multicenter,
randomized, double-blind, placebo-controlled clinical
trial conducted in the setting of Italian general practice.
The primary, experimental, aim of R&P is to assess the
efficacy and safety of n-3 PUFAs in reducing cardiovascu-
lar mortality (including sudden death) and hospitaliza-
tion for cardiovascular reasons in patients at high CVD
risk but with no history of MI. The secondary, epidemio-
logical, aim is to assess the feasibility of adopting current
guidelines in everyday clinical practice in order to opti-
mize all available preventive strategies in people at high
cardiovascular risk (Figure 1).
Eligibility criteria were one of the following: 1) clinical
evidence of atherosclerotic CVD such as angina pectoris,
peripheral artery disease, previous ischemic stroke, tran-
sient ischemic attack or revascularization procedure; 2)
multiple risk factors (at least four CV risk factors in non-
diabetic patients and one or more in diabetics) including:
old age (≥ 65 years), male sex, history of arterial hyper-Rischio and Prevenzione Investigators Trials 2010, 11:68
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tension, history of hypercholesterolemia, smoking, obe-
sity (BMI ≥30 kg/m2), family history of premature CVD
(<55 years in father or brother; <65 years in mother or sis-
ter); 3) other conditions putting the patient at high car-
diovascular risk according to the general practitioner
(GP)'s judgement.
The exclusion criteria were: prior MI, allergy to n-3
PUFAs, pregnancy, diseases with predictable poor short-
term prognosis, and foreseeable psychological or logistic
difficulties that would affect compliance with the project.
Intervention strategies
Patients were randomly allocated to receive one capsule
daily of 1 g n-3 PUFAs (850-882 mg EPA and DHA as
ethyl esters with an average ratio of 1.0 to 1.2) or placebo
(olive oil).
At the beginning and during the follow-up all patients
were also evaluated and treated by their GPs according to
current guidelines in order to optimize their CV risk
management. At each visit GPs discussed with the
patients their level of CV risk and the possible therapeu-
tic strategies to be adopted or improved (e.g., control of
blood pressure, glucose or cholesterol levels, weight
reduction, stop smoking, increase physical activity,
choose healthier foods, prescription of antiplatelets, etc.),
and the therapeutic targets to be achieved in the next
study period, completing an ad hoc check list.
Study procedures
GPs were selected either through participation in previ-
ous research projects [16,35] or through the investigators'
registries at local health units. GPs were invited to attend
training meetings held with the patronage of local health
units. During these meeting guidelines on cardiovascular
prevention were presented and discussed.
Eligible patients were informed and gave their written
consent to the study. Treatment was centrally allocated by
telephone according to a computer-generated random-
ization list stratified by GP.
Data collection and follow-up
Patients are followed by their GPs according to their
usual practice, no additional instrumental/laboratory
tests are required for the study. Data collection is sched-
uled annually, and follow-up is planned to last five years.
At enrolment, height, weight, waist circumference,
heart rate and blood pressure were measured. History of
CVD, risk factors and information on demographic fac-
tors, social status, lifestyle habits, laboratory tests and
current medical therapies were collected. Patients were
also required to complete a simple questionnaire about
dietary habits, physical activity during leisure time, social
life, psychological status and perceived CV risk level.
Clinical outcomes and adverse events are recorded
w h e n  t h ey  a d vi s e  a n d  n o t i f i ed  w i t h  a n  ad hoc clinical
form.
Follow-up clinical visits include checking compliance
and tolerance to the treatment. Updated information on
any new diagnosis of CVD, control of risk factors,
changes in lifestyle or dietary habits, and use of medica-
tions is also collected
All patients are to be followed up to the scheduled end
of study, regardless of adherence to or discontinuation of
the treatment for any reason. Study treatments are sup-
plied according to the local health units' procedures.
Efficacy
The main endpoint of the trial testing the efficacy of n-3
PUFA treatments is cardiovascular death or hospitaliza-
tion for cardiovascular reasons. Secondary efficacy mea-
sures include: 1) the cumulative rate of death, non-fatal
MI, non-fatal stroke; 2) the cumulative rate of cardiovas-
cular death, non-fatal MI, non-fatal stroke; 3) coronary
deaths; 4) sudden deaths. Additional analysis will be done
on each component of the primary endpoint and in spe-
cific subgroups of patients corresponding to different risk
levels or comorbidity. A specific evaluation is also
planned of the benefit of the treatment on the reduction
of fatal and non-fatal coronary and arrhythmic events. All
outcome events are adjudicated by an ad hoc committee
blind to the treatment allocation on the basis of pre-
agreed definitions and procedures. All reports include a
narrative summary and supporting documentation for
Figure 1 Rischio & Prevenzione study design. n-3PUFA indicate 
polyunsaturated fatty acids.
Patients at high cardiovascular risk
Randomization
Adoption of strategies aimed at optimizing the 
cardiovascular risk profile
Annual follow-up visits for end-points
n-3 PUFA 1 
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every event (e.g. clinical records, death certificates and
any other relevant documentation).
To assess the feasibility of optimizing cardiovascular
prevention in the study population, the preventive strate-
gies adopted and the goals chosen at the outset and dur-
ing follow-up will be analyzed, as well as their efficacy in
terms of risk factor control and therapeutic targets
attained.
Safety
All serious adverse events (defined as fatal, life-threaten-
ing, requiring or prolonging hospitalization, permanently
disabling or incapacitating, which may jeopardize the
subject or which may require medical or surgical inter-
vention), not necessarily drug-related, are reported on a
standard form and communicated to the study Coordi-
nating Center within 24 hour of notification of their
o c c u r r e n c e .  S a f e t y  i s  m o n i t o r e d  b y  a n  e x t e r n a l  D a t a
Safety Monitoring Board (DSMB).
Statistical aspects
The primary endpoint at the start of the study was the
cumulative rate of death plus non-fatal-MI and non-fatal
stroke. The expected incidence of the primary endpoint
was based on the literature and on the events observed in
a subgroup of patients of a previous trial conducted in a
similar setting of patients and GPs (16). Overall, the rate
of events included in the primary endpoint was expected
to be 2% per year (10% in five years). The goodness of
these sample size calculation was to be assessed after one
year of follow-up and the observed rate of events was in
fact much lower than expected (1.4% instead of 2%).
Because n-3 PUFA seemed to have a positive influence
on various CV outcomes besides the MI and stroke, and
considering the increasing burden for public health sys-
tems of CV events requiring hospitalization, time to first
occurrence of CV death and hospitalization for CV rea-
son was then established as the primary efficacy endpoint
of the trial. The expected cumulative rate of these com-
bined end points during the five-year follow-up was
assumed to be 15%. The minimum clinically relevant
beneficial effect of the test treatment on the cumulative
endpoint is set at 15% relative risk reduction (2.25% abso-
lute risk reduction). Accordingly, to detect the efficacy of
treatment with a power of 90% and α = 0.05 at least
11,202 patients must be included with a mean follow-up
of five years and ≤10% drop outs. To guarantee adequate
study power, an event-driven approach was adopted and
patients will be followed-up until 1,383 events occur for
the primary endpoint.
Statistical differences in the baseline characteristics of
the treatment groups will be assessed with the χ2 test for
categorical variables and t test for continuous variables.
Treatment efficacy on the primary endpoint, and on each
single component, will be assessed using a Cox's propor-
tional hazards' model [36], and the results will be
expressed as hazard ratio (HR) estimates with 95% confi-
dence intervals (CIs). Efficacy analyses will be adjusted
for covariates found to be unbalanced between ran-
domised treatments. Kaplan-Meyer estimates of the sur-
vival curves will be presented [37]. Time of occurrence of
primary combined endpoint will be calculated according
to the following hierarchy: time of occurrence of cardio-
vascular mortality or time of first occurrence of hospital-
ization for CV reasons.
An interim analysis to assess the efficacy on the pri-
mary endpoint is scheduled at approximately half the
expected events. This will be monitored using the
sequential procedure of Peto [38] and the study will be
stopped when the corresponding significance level of evi-
dence reaches α ≤ 0.001.
All analyses will be according to the intention-to-treat
approach in which all randomized patients are included,
regardless of the adherence to study treatment. A per
protocol analysis will be done for patients who take at
least 80% of their treatment.
Ethical/regulatory aspects
The ethical conduct of the study is regulated by the last
revision of the Helsinki Declaration. The study is consis-
tent with Good Clinical Practice (GCP) principles and
procedures, as described in the ICH Harmonized Tripar-
tite Guideline for Good Clinical Practice (1996); Directive
93/39/CEE The Rules Governing Medicinal Products in
the European Community. The study complies with Ital-
ian law, Directive 10 May 2001, "Controlled Clinical Tri-
als in the Setting of General Practice and Pediatrics".
The study protocol was approved by the Italian health
authorities, the Ethics Committee of the Chairman's
Institution and by the local Ethics Committees. An ad hoc
insurance policy was stipulated for patients and GPs.
This study is registered in a public clinical trial database
(ClinicalTrials.gov NCT00317707).
Trial update
A total of 1,620 GPs attended 34 local training meetings
organized throughout Italy; 860 (58%) out of 1486 GPs
who initially agreed to join the study started to recruit
patients (Figure 2). Between February 2004 and March
2007, 12,513 patients were enrolled. Each GP admitted an
average of 14 patients (range 1-79); respectively 271
(31.5%), 564 (65.6%), and 25 (2.9%) GPs recruited ≤10, 11-
20, and more than 20 patients.
The main inclusion criterion was diabetes mellitus plus
one or more CV risk factors (46.9%). About 30% of
patients were admitted because of clinical evidence of
atherosclerotic CV, except a history of MI: angina pecto-
ris (12.0%), revascularization procedures (8.8%), periph-Rischio and Prevenzione Investigators Trials 2010, 11:68
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eral artery disease (7.8%), previous transient ischemic
attack (8.1%) or ischemic stroke (4.0%). Multiple CV risk
factors (≥4 risk factors, except diabetes mellitus) were the
inclusion criterion for 21.1% of patients. Less than 1%
were included for other reasons. The main baseline fea-
tures of the study population are shown in Table 1.
Discussion
As shown in Figure 2 and Table 1, the first and certainly
one of the most important results of the study is that it
proved feasible to create a network of collaborating phy-
sicians to generate a prospective cohort adequately repre-
sentative of practice throughout the country. The GPs'
participation is mainly motivated by the acknowledgment
that the study is an expression of the duty to continuous
professional education. It is also a reminder of the close
links between research and practice: the only way to be
informed and responsible about whatever is uncertain or
unknown, is to investigate it through a research protocol.
The protocol therefore - as a general design, but even
more as an operational trial - is the product of a truly col-
lective interplay among dozens of colleagues, and it was
open to discussion at the 34 presentations organized
throughout the country. One of the GCP requirements -
continued education meetings for investigators to verify
quality and surveillance of data collection - has been used
as an opportunity for sharing and optimizing a project,
more than just a teaching exercise on the technicalities of
trial procedures.
Figure 2 Rischio & Prevenzione research network. Red circle = Lo-
cal health units in the Italian regions participating in the study. The na-
tion-wide research network comprised 860 general practitioners in 57 
local health units, who admitted 12,513 patients to the study.
Table 1: Baseline characteristics of Risk & Prevention 
participants
% or mean (SD)
Age (years)
Mean 63.9 (9.5)
≤50 7.4
51-59 22.9
60-69 39.6
70-79 27.0
≥80 3.0
Males 61.5
Previous CVD 29.6
Cardiovascular risk factors
Hypertension 84.6
Hypercholesterolemia 71.1
Diabetes mellitus 59.9
Obesity 48.6
Family history of premature CVD 31.1
Cigarette smokers 21.7
Unhealthy diet 63.9
Physical inactivity 56.1
BMI (kg/m2) 29.3 (4.9)
SBP (mmHg) 140.2 (15.2)
DBP (mmHg) 82.7 (8.2)
Heart rate (bpm) 74.4 (8.4)
Total cholesterol (mg/dL) 215.9 (42.6)
LDL cholesterol (mg/dL) 132.1 (36.4)
HDL cholesterol (mg/dL) 51.1 (13.3)
Triglycerides (mg/dL) 168.7 (99.8)
Fasting blood glucose (mg/dL) 132.8 (46.7)
* HbA1C (%) 7.0 (1.5)
Medical treatment
ACE inhibitors 45.1
ARBs 21.9
Diuretics 41.5
Calcium - channel blockers 28.2
β-blockers 20.6
Oral hypoglycemic drugs 44.1
Insulin 6.6
Statins 41.1
Antiplatelet agents 41.4
*in diabetic patients
CVD, cardiovascular disease; BMI, body mass index; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; LDL, low-density 
lipoprotein, HDL, high-density lipoprotein, HbA1C, glycated 
hemoglobin, ACE, angiotensin-converting enzyme; ARB, 
angiotensin receptor blockerRischio and Prevenzione Investigators Trials 2010, 11:68
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Consistently with this approach, the inclusion criteria
in the trial are not just a list of "objective" data: they
mimic the process of an informed decision, which is a
mix of documented knowledge, of "perceived" overall
clinical condition of risk, and a judgment of opportunity.
The epidemiological variability of the study population is
not only expected (as explicitly set out in the protocol),
but needed, to ensure the population is really representa-
tive, and therefore the descriptive and experimental
results once they become available can be transferred
appropriately.
The patients'actual level of CV risk is lower than
expected. However, this is not surprising: beside the fact
that the cohort is younger than expected, current patients
are more widely exposed to preventive measures. In fact,
the rate of events reported in previous or observational
studies reflects clinical practice at that time and overesti-
mates the current risk.
The decision to modify the study endpoint fits well
with the public health-oriented design of this GP based
project and shows that a trial is simply one part of a strat-
egy of comprehensive prospective monitoring and assess-
ment of all those patients deemed to be at a specific risk.
Their epidemiological outcomes over the medium-long
term provide the most important knowledge from which
to interpret the experimental results, which will show
whether or not the "new" treatment adds a specific
advantage to the "natural" history of this population (i.e.
under the GPs' routine care).
Finally, the scientific interest and "modernity" of the
experimental hypothesis tested in R&P is confirmed by
the GISSI-HF trial results which further support the ben-
efit of n-3 PUFA on mortality seen in GISSI-Prevenzione
[17], confirming a significant reduction of deaths in
patients with heart failure [39]. Similarly, the benefit of n-
3 PUFA in Japanese people suggests that it might be repli-
cated in other populations, and might be even more sub-
stantial with higher levels of intake [40]. Novel results like
this in the field of cardiology fuel the hypothesis of anti-
arrhythmic and anti-atherosclerotic effects of n-3 PUFA
and show how important it is to testing their efficacy in a
GP's population of patients at high CV risk.
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